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Abstract
Over the last four years, I have developed a research focus examining the intersections of race,
place, and health.1–11 My M.D. Honors Thesis reflects a snapshot of these efforts. In this
collection of brief research reports, I leverage area-based measures to investigate structural
inequities in three contexts: the HIV epidemic in our hyperlocal community,1 the early stages of
the COVID-19 pandemic,2,3 and clinical trials for novel COVID-19 therapeutics.4 I apply novel
social epidemiologic tools to measure and explore disparate outcomes. And, in reflecting upon
my findings, I discuss concrete implications for clinicians, researchers, and policymakers alike.
Chapter 1: Neighborhood-Level Deprivation and Racial Inequities in HIV Viral Suppression1
Human immunodeficiency virus (HIV) is a treatable chronic disease. Yet, geographic and racial
inequities across the HIV care continuum are persistent, even in the U.S. Midwest. Using the
Area Deprivation Index, a novel measure of neighborhood-level disadvantage, I showed that
Black-White disparities in HIV viral suppression among our clinic population are explained by
neighborhood deprivation. Our findings highlighted how structural racism, through
longstanding place-based disinvestment, directly contributes to disparate HIV outcomes.
Chapter 2: County-Level Social Vulnerability and COVID-19 Cases & Deaths2,3
While it is now widely recognized that the COVID-19 pandemic has had an outsized impact on
marginalized and minoritized communities, the pandemic’s inequitable trajectory was not as
obvious during the early stages. Leveraging publicly available data as of mid-April 2020 and the
validated CDC/ATSDR Social Vulnerability Index, I showed how greater prevalence of
population-level characteristics like racial/ethnic minority status, limited English proficiency,
poverty, unemployment, crowded housing, and poor transportation access are directly
associated with disease incidence and death. Our findings informed risk prioritization efforts
across the country and offer an evidence-based framework for allocation of scarce resources.
Chapter 3: Census Tract-Level Inequities in Access to COVID-19 Therapeutic Trials4
Geography is a key determinant of access to health care yet is often unexplored as a
determinant of clinical trial enrollment. Using publicly available data from ClinicalTrials.gov, I
geocoded the locations of 2,095 COVID-19 biomedical trial sites and calculated the driving
distance from each U.S. Census tract center of population to the nearest site. I identified that
nearly one-third of the overall US population, over one-half of the Native American population,
and over three-fourths of the rural population lived more than an hour away from the nearest
trial site. Of further concern, Black and Hispanic populations lived closer to trial sites than other
populations, yet several studies highlighted the underrepresentation of these populations in
major COVID-19 trials. Our findings demonstrated that geographic accessibility alone may not
improve representative trial enrollment in the absence of additional structural interventions.
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CHAPTER 1. Neighborhood-Level Deprivation and Racial/Ethnic
Inequities in HIV Viral Suppression
Rohan Khazanchi, MPH
College of Medicine, University of Nebraska Medical Center

Harlan Sayles, MS
Department of Biostatistics, College of Public Health, University of Nebraska Medical Center

Sara H. Bares, MD; Susan Swindells, MBBS; Jasmine R. Marcelin, MD
Division of Infectious Diseases, University of Nebraska Medical Center

Introduction
Since the advent of combination antiretroviral therapy, human immunodeficiency virus (HIV)
infection has become widely regarded as a treatable chronic disease. However, given the
persistence of racial/ethnic and geographic differences in HIV outcomes, combating HIV-related
disparities is now a primary objective of federal initiatives to end the HIV epidemic.12 Black and
Hispanic people with HIV (PWH) face inequities across the HIV care continuum; disparities in
linkage to care, retention in care, treatment adherence, and viral suppression continue to impact
efforts to curb HIV transmission and disease progression.13,14
Structural racism and neighborhood segregation in the United States are fundamental causes of
health inequities due to downstream differences in socioeconomic, educational, and
employment opportunities.15 Living in a disadvantaged neighborhood has been linked to
numerous adverse health outcomes including decreased rates of HIV viral suppression16–20;
thus, policymakers and clinicians must consider socioecological context when proposing
interventions. The Area Deprivation Index (ADI) is a validated, summative index of
neighborhood-level inequalities composed of 17 education, employment, housing quality, and
poverty measures drawn from 2011-2015 U.S. Census American Community Survey data.21
Since ADI can be easily ascertained based on patient ZIP codes, it may have utility for clinician
and systems-level interventions.22
While prior studies have identified that neighborhood context may impact rates of HIV viral
suppression, these works have focused on large metropolitan areas or, more recently, highincidence geographic regions (i.e. the Southern U.S.).16–19 Neighborhood-level contributions to
HIV outcomes have not been assessed in the U.S. Midwest.
The Omaha metropolitan area has a Black/White dissimilarity index (a validated measure of
neighborhood segregation, reported as the percentage of one group that would have to move
across neighborhoods to be distributed the same way as the second group) of 69.8%, placing it

R. Khazanchi | Interrogating Race and Place-Based Inequities in HIV and COVID-19 | Page 5

in the 82nd percentile among U.S. metropolitan areas.23 In a study of our clinic’s population of
PWH from 1997-2007, we reported that Black PWH with advanced disease had higher mortality
rates and Hispanic patients had higher initial viral load but similar mortality when compared to
White PWH over the study period, even after controlling for patient-level confounders.24 The
present work aims to elucidate contributions of neighborhood-level deprivation and rurality to
persistent racial/ethnic disparities in a contemporary U.S. Midwest cohort of PWH.

Methods
We conducted a retrospective cohort study of adult PWH attending the Ryan White-funded
University of Nebraska Medical Center HIV Clinic in Omaha, Nebraska between January 1,
2012 and January 1, 2018. We include living and deceased patients older than 19 years old with
a diagnosis of HIV. We excluded patients whose records were missing key demographic
characteristics (income, self-reported race), a 9-digit ZIP code, or at least one recorded HIV-1
RNA value within the study period. We also excluded patients lost to follow-up after one visit
and patients with a lapse in care greater than 2 years. Based on each patient’s most recent visit,
we collected sociodemographic and clinical characteristics. HIV viral suppression was defined
as most recent HIV-1 RNA < 200 copies/mL, in concordance with recent national guidelines.25
We grouped patient-reported race/ethnicity into Non-Hispanic White, Non-Hispanic Black,
Hispanic, and Other (which included Asian, Pacific Islander, and Native American patients)
categories. We assessed neighborhood disadvantage by linking 9-digit ZIP codes to ADI values
via the University of Wisconsin’s Neighborhood Atlas tool, version 2.0, based on 2011-2016 U.S.
Census data.21 ADI values represent national percentile rankings of neighborhood disadvantage
from 1 to 100, with higher numbers indicating greater disadvantage. We assessed rurality using
Rural-Urban Commuting Area (RUCA) codes, version 2.0, which link ZIP codes to a ruralurban index based on population dispersion and commuting patterns.26 We aggregated RUCA
codes into Urban and Rural groups using Categorization C.26
We compared racial/ethnic differences in patient characteristics using Fisher’s exact tests for
categorical measures (HIV viral suppression, sex, annual income ≤ 138% of the federal poverty
level) and ANOVA for continuous measures (age). We used univariate and multivariate logistic
regressions to examine the independent influences of sociodemographic characteristics on the
odds of viral suppression. We conducted all analyses using R Statistical Software v3.6.3 (R
Foundation for Statistical Computing) and considered p < 0.05 to be statistically significant. This
study was granted exempt review status by the UNMC Institutional Review Board.
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Results
In total, we included 947 PWH after excluding 305 PWH missing demographic data, 188
missing ZIP codes, and 27 without a recorded HIV-1 RNA. White PWH had a higher average
age (48 years) than all other racial/ethnic groups (43 years, p < 0.001). Sex differences were also
present between racial/ethnic groups, with Black (37% female) and Other (32%) groups having
more female PWH than White (17%) and Hispanic (20%) groups (p < 0.001). Black PWH were
more likely to have an annual income ≤ 138% of the federal poverty level (68%) than White
(51%), Hispanic (57%), and Other (58%) PWH (p < 0.001). White (15%) and Hispanic (12%) PWH
were more likely to live in rural areas than Black (2%) and Other (5%) PWH (p < 0.001).
ADI was also significantly different across racial/ethnic groups, with White (mean 62 ± S.D. 22)
and Other (64 ± 25) PWH having lower mean ADI values (i.e., less neighborhood deprivation)
than Black (72 ± 22) and Hispanic (72 ± 20) PWH (p < 0.001). To illustrate the implications of
racial segregation on neighborhood deprivation in our hyperlocal context, the relationship
between ADI and the distribution of racial/ethnic groups in the greater Omaha area is mapped
in Figure 1.
In comparison with White PWH, Black PWH had significantly lower rates of viral suppression
(90% vs. 84%, p = 0.016), but no significant difference was noted between White and Hispanic
(91%, p = 0.310) or Other (91%, p = 0.838) PWH. However, as shown in Table 1, in multivariate
models controlling for age, sex assigned at birth, income, ADI, and rurality, Black PWH did not
have significantly different rates of viral suppression from White PWH (aOR 0.90; p = 0.681).
Age (aOR 1.04; p < 0.001), low income (aOR 0.47; p = 0.002), and ADI (aOR 0.88 for a decile
increase in ADI; p = 0.023) were independently associated with viral suppression. Conclusions
for the variables included were unchanged after addition of insurance status and/or removal of
income from the model.

Discussion
Disparities in HIV viral suppression have persisted among Black PWH at our HIV clinic.
However, after controlling for demographic characteristics and structural factors including
neighborhood deprivation, racial differences in viral suppression were no longer robust.
Racial differences in viral suppression identified in this 2012-2018 study period are consistent
with the longitudinal disparities noted by our clinic in a previous 1997-2007 study.24 While ADI
and income were inversely associated with viral suppression after controlling for covariates,
rurality was not significantly associated with viral suppression in our patient population. In
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both univariate and multivariate models, Hispanic PWH do not have lower rates of viral
suppression noted despite having the same mean ADI as Black PWH.
Modern antiretroviral therapy has dramatically impacted disease course and quality of life for
PWH. However, even in regions of the United States with relatively low HIV incidence and
mortality rates like the Midwest, racial disparities in HIV disease outcomes remain prevalent. In
2019, the U.S. Department of Health & Human Services ambitiously proposed the Ending the
HIV Epidemic plan for communities hardest hit by the HIV epidemic, targeting geographic
hotspots with high incidence rates that will require expanded HIV prevention and treatment
activities.12 This study reinforces the notion that, in addition to geographic priorities, particular
patient populations continue to bear an increased burden of HIV disease activity and may also
require targeted intervention to improve disease outcomes.
Beyond just recognizing the persistence of these disparities, future interventions should
consider the structural forces that perpetuate racial differences in HIV outcomes. Omaha, like
many metropolitan areas, is a city with historic redlining and housing segregation that have
contributed to significant present-day geographic differences in neighborhood racial
composition and resource availability.15,27 Particularly in cities like Omaha, racial/ethnic and
ADI disparities among PWH suggest structural racism (intergenerational and systems-level
forces influencing patient outcomes), rather than race alone, as a risk factor for HIV viral nonsuppression.28,29 This work demonstrates associations between neighborhood deprivation,
individual income, and race/ethnicity that are especially prominent in segregated metropolitan
areas like Omaha. Elucidating these influences may help inform systemic and place-based
interventions intended to improve HIV outcomes.20
There are several limitations to our findings. First, the retrospective and single-center design
limit the study’s generalizability. Second, available data do not address heterogeneity between,
for example, migrants from sub-Saharan Africa and U.S.-born Black Americans30; disaggregated
race/ethnicity data are needed. Finally, the exclusion of patients without a documented ZIP
code likely removed our patients with unstable housing from the study population and may
contribute to underestimation of viral non-suppression given the strong inverse association
between housing instability and viral suppression.31 However, a key strength of our study is the
unique use of readily available electronic health record data to link patient clinical and
demographic characteristics with an area-based socioeconomic measure.

Conclusion
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Despite continued improvements in HIV prevention, treatment, and access to care, inequities in
HIV viral suppression persist in the U.S. Midwest. In multivariate analyses accounting for
neighborhood deprivation and other demographic characteristics, Black race was no longer an
independent predictor of viral suppression. Recognizing the contributions of socioecological
factors rooted in structural racism, like neighborhood deprivation, may help elucidate
fundamental causes of racial/ethnic disparities and target opportunities for intervention.

Additional Notes
Acknowledgements. First and foremost, the authors want to thank our patients. The authors
would also like to thank Dr. Purnima Guda from the UNMC Center for Clinical & Translational
Research and Mr. Sean Reiling from Nebraska Medicine for support during data collection.
Author contributions. R.K., H.S., S.H.B., and J.R.M. designed the study and interpreted the data.
H.S. performed statistical analyses. All authors contributed to drafting and revisions of the
manuscript, and all authors reviewed a final version of the work.
Funding. The authors report no financial support for this work.
Prior presentations: A portion of this study was presented as a poster at IDWeek 2020 and
received an IDSA IDWeek Mentorship Program travel award.
Potential conflicts of interest. S.H.B. reports grant funding to her institution from Gilead Sciences.
S.S. reports grant funding to her institution from ViiV Healthcare. All other authors have no
conflict of interests to declare.

R. Khazanchi | Interrogating Race and Place-Based Inequities in HIV and COVID-19 | Page 9

FIGURE
Figure 1 – Comparative visualization of (A) Area Deprivation Index and (B) racial composition
of Greater Omaha Area.

Footnotes: ADI visualization generated via the University of Wisconsin’s Neighborhood Atlas tool, version 2.0, based
on 2011-2016 U.S. Census American Community Survey data.21 Racial Dot Map generated via the University of
Virginia’s Weldon Cooper Center for Public Service, based on 2010 U.S. Census decennial data. 32
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TABLE
Table 1 – Independent predictors of HIV viral suppression.

Patient Demographic or
Neighborhood Characteristic

Suppressed, Not Suppressed,
n=851
n=96
Adjusted Odds
p-value
Ratio (95% CI)‡
Mean (S.D.)
Mean (S.D.)
or N (%)

or N (%)

Age, years

46.2 (11.6)

40.6 (11.1)

1.04 (1.02, 1.06)

<0.001

Sex Assigned at Birth
Male
Female

657 (77%)
194 (23%)

66 (69%)
30 (31%)

Ref.
0.71 (0.44, 1.16)

Ref.
0.170

Race/Ethnicity
Non-Hispanic White
Non-Hispanic Black
Hispanic
Other (Native American, Asian)

452 (53%)
241 (28%)
123 (14%)
35 (4%)

44 (46%)
41 (43%)
8 (8%)
3 (3%)

Ref.
0.90 (0.55, 1.48)
2.15 (0.96, 4.81)
1.57 (0.45, 5.50)

Ref.
0.681
0.062
0.480

456 (54%)

71 (74%)

0.47 (0.29, 0.76)

0.002

Rurality*
Urban
Rural

758 (89%)
93 (11%)

88 (92%)
8 (8%)

Ref.
1.12 (0.50, 2.47)

Ref.
0.787

Area Deprivation Index (ADI)†

65.7 (22.2)

72.6 (22.3)

0.88 (0.79, 0.98)§

0.023

Income ≤ 138% Federal Poverty
Level

Footnotes: Rurality defined using Categorization C of Rural-Urban Commuting Area codes, Version 2.0, from the
University of Washington WWAMI Rural Health Research Center.26
† ADI defined according to University of Wisconsin’s Neighborhood Atlas database (v2.0). 21 ADI values represent
national percentile rankings of neighborhood disadvantage from 1 to 100, with higher numbers representing a
greater level of disadvantage.
‡ Adjusted odds ratios and p-values were derived from multivariate logistic regression models for binary indicator
variable for most recent HIV RNA < 200 copies/mL.
§ Adjusted odds ratio and 95% CI presented are for a 10-unit (i.e., one decile) change in ADI.
*
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CHAPTER 2. County-Level Social Vulnerability and COVID-19 Cases &
Deaths
Rohan Khazanchi, MPH
College of Medicine, University of Nebraska Medical Center
School of Public Health, University of Minnesota

Evan R. Beiter, BA; Suhas Gondi, BA; Adam L. Beckman, BS
Harvard Medical School

Alyssa Bilinski, PhD
Harvard Graduate School of Arts & Sciences

Ishani Ganguli, MD, MPH
Division of General Internal Medicine & Primary Care, Brigham & Women’s Hospital

Introduction
In past pandemics, vulnerable populations faced greater disease burden and decreased testing
and treatment access.33 As coronavirus disease 2019 (COVID-19) spreads in the United States,
concern is growing that even the early stages of this pandemic have disproportionately
impacted vulnerable communities.34–36 However, the relationship between social vulnerability
and COVID-19 diagnosis and mortality in rural and urban communities remains unknown. In
this work, we leveraged publicly available data to examine the association between social
vulnerability and COVID-19 outcomes at the actionable county level.

Methods
We performed a county-level, cross-sectional analysis using COVID-19 case and death rates
compiled by The New York Times from health agency reports as of April 19, 2020. We stratified
counties into quartiles using the U.S. Centers for Disease Control’s Social Vulnerability Index
(SVI), a validated measure of community resilience during natural disasters and disease
outbreaks across four domains: socioeconomic status, household composition and disability,
minority status and language, and housing and transportation.37 We defined urbanicity using
the U.S. Department of Agriculture Economic Research Service’s 2013 Urban Influence Codes.38
We merged data sources using Federal Information Processing Standard (FIPS) codes, including
counties with a linkable FIPS code and at least one COVID-19 case.
Our primary outcomes were positive tests per capita and COVID-19 deaths per capita. We built
population-weighted, quasi-Poisson regression models to compare outcomes between the first
and fourth quartile of counties by SVI and each SVI domain. In secondary analyses, we
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stratified counties by rural and urban classification. We included state fixed effects to account
for heterogeneity in policies and disease spread. We analyzed data with R Statistical Software
v3.6.3 (R Foundation for Statistical Computing), and considered P < 0.002 significant after
Bonferroni correction. This study was approved by Partners Healthcare Institutional Review
Board.

Results
As of April 19, there were 612,404 confirmed cases and 25,978 COVID-19 deaths across the 2,754
(of 3,143 total) counties analyzed (mean cases 102.2 per 100,000 [SE 3.8], deaths 4.0 per 100,000
[0.2]). Compared to those in the least vulnerable counties, people in the most vulnerable
counties had 1.63-fold greater risk of COVID-19 diagnosis and 1.73-fold greater risk of death
(Table 1). When considering only the minority status and language domain, people in the most
vulnerable counties had 4.94-fold and 4.74-fold greater risks of COVID-19 diagnosis and death,
respectively. Cases per capita in the least and most vulnerable counties by minority status were
mapped to visualize regional trends (Figure 1). Similarly, people in the most vulnerable
counties by socioeconomic status (relative risks [RR] of 1.42 and 1.7) and housing and
transportation (RR 1.52 and 1.32) domains had greater risk of COVID-19 diagnosis and death.
Vulnerability by the household composition and disability domain was not associated with
differential risk.
These trends persisted among urban counties alone. However, among rural counties alone, the
most vulnerable counties by minority status and language had greater risk of COVID-19
diagnosis (RR 3.74), while associations with overall SVI, socioeconomic status, and housing and
transportation were no longer significant.

Discussion
Greater social vulnerability is associated with increased risk of COVID-19 incidence and death.
In urban and rural counties alike, this is driven by differences across the minority status and
language domain, consistent with early reports of increased COVID-19 prevalence and
mortality among minorities.34 Factors such as poverty, unemployment (socioeconomic status
domain), crowded housing, and vehicle access (housing and transportation domain) were also
associated with increased COVID-19 diagnosis and mortality in urban areas.
In rural communities, minority status persists as a driver of increased COVID-19 cases. The
disproportionate impact of COVID-19 on minority and non-English speaking communities in
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both urban and rural areas may reflect compounding effects of structural racism, increased
burden of chronic disease risk factors, and health care access barriers.
Our study has limitations. The cross-sectional, county-level design does not allow for causal,
individual-level inferences. Analyses did not account for all county-level differences in testing
rates or pandemic progression, although state fixed effects accounted for geographic
heterogeneity in state-level policy responses. As case reporting improves, analyzing more
granular groupings of non-metropolitan counties may further elucidate rural trends.
In light of upcoming federal guidelines for county-level COVID-19 risk stratification and
heterogeneity in the accuracy and comprehensiveness of demographic data,36,39 our findings
reemphasize the need for standardized collection of sociodemographic characteristics and
place-based allocation of scarce resources. Targeted interventions addressing geographically
variable social vulnerabilities will be necessary to improve inequitable outcomes of the COVID19 pandemic, and to redress health disparities more broadly.
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TABLES
Table 1 – COVID-19 cases and deaths per capita between most and least socially vulnerable
rural and urban counties.

Social Vulnerability Index‡
Total
Urban§
Q1=315,Q4=202
Rural§
Q1=319,Q4=521
Socioeconomic Status||
Total
Urban
Q1=351,Q4=163
Rural
Q1=296,Q4=547
Household Composition
& Disability¶
Total
Urban
Q1=436,Q4=169
Rural
Q1=251,Q4=522
Minority Status &
Language††
Total
Urban
Q1=162,Q4=377
Rural
Q1=463,Q4=329
Housing Type &
Transportation‡‡
Total
Urban
Q1=291,Q4=286
Rural
Q1=321,Q4=444

Q1

Q4

n=

634
92.9 (6.6)
3.71 (0.39)
119.7 (11.7)
4.94 (0.64)
66.3 (5.9)
2.49 (0.43)
647
102.8 (7.4)
3.74 (0.37)
130.1 (11.3)
5.12 (0.59)
70.4 (8.8)
2.11 (0.39)
687

723
122.9 (7.6)
5.42 (0.55)
166.2 (18.0)
7.39 (1.23)
106.2 (7.9)
4.66 (0.59)
710
112.4 (7.1)
5.08 (0.54)
148.8 (17.8)
6.67 (1.35)
101.5 (7.4)
4.61 (0.57)
691

n=

131.3 (9.8)
4.81 (0.44)
158.9 (14.0)
6.24 (0.63)
83.4 (10.2)
2.32 (0.47)
625

n=

n=
Cases per 100,000
Deaths per 100,000
Cases per 100,000
Deaths per 100,000
Cases per 100,000
Deaths per 100,000
n=
Cases per 100,000
Deaths per 100,000
Cases per 100,000
Deaths per 100,000
Cases per 100,000
Deaths per 100,000

Cases per 100,000
Deaths per 100,000
Cases per 100,000
Deaths per 100,000
Cases per 100,000
Deaths per 100,000

Cases per 100,000
Deaths per 100,000
Cases per 100,000
Deaths per 100,000
Cases per 100,000
Deaths per 100,000

Cases per 100,000
Deaths per 100,000
Cases per 100,000
Deaths per 100,000
Cases per 100,000
Deaths per 100,000

Relative
Risk†

95% CI

1.63*
1.73*
1.77*
1.87*
0.92
0.66

1.49 – 1.78
1.55 – 1.93
1.57 – 2.00
1.60 – 2.17
0.68 – 1.24
0.36 – 1.19

1.42*
1.71*
1.61*
1.86*
0.64
0.77

1.26 – 1.60
1.47 – 1.98
1.36 – 1.91
1.50 – 2.30
0.44 – 0.94
0.36 – 1.62

100.8 (6.7)
4.62 (0.53)
125.8 (16.4)
6.24 (1.26)
92.7 (7.1)
4.09 (0.57)
706

0.85
1.10
1.00
1.29
1.05
1.42

0.73 – 0.99
0.93 – 1.30
0.79 – 1.28
1.01 – 1.66
0.82 – 1.35
0.95 – 2.12

51.2 (2.6)
2.11 (0.24)
54.1 (3.8)
1.88 (0.24)
50.2 (3.2)
2.18 (0.31)
612

158.1 (11.1)
5.86 (0.52)
203.2 (18.0)
8.14 (0.85)
106.4 (11.4)
3.25 (0.48)
730

4.94*
4.74*
5.02*
5.30*
3.74*
1.60

3.91 – 6.24
3.55 – 6.32
3.20 – 7.88
3.03 – 9.28
2.66 – 5.25
0.88 – 2.93

82.1 (4.7)
2.84 (0.28)
100.8 (7.4)
3.84 (0.44)
65.1 (5.7)
1.92 (0.34)

140.1 (10.0)
5.81 (0.58)
190.4 (21.0)
7.42 (1.03)
107.7 (8.9)
4.77 (0.67)

1.52*
1.32*
1.53*
1.29*
1.08
1.27

1.35 – 1.72
1.14 – 1.53
1.30 – 1.81
1.05 – 1.59
0.84 – 1.37
0.87 – 1.84

Abbreviations: Q1 = least vulnerable quartile; Q4 = most vulnerable quartile. Q1 and Q4 are reported as mean (SE) values.
Footnotes: * Statistically significant result, based on P < 0.002 after Bonferroni correction.
† Relative risk was calculated from population-weighted, quasi-Poisson regression models with state fixed effects.
‡ The Social Vulnerability Index is an aggregate of all four domains, each calculated based on variables from the 2014-2018 US Census
American Community Survey data.
§ Urban and Rural characteristics were determined from the U.S. Office of Management & Budget categorization of the U.S. Department of
Agriculture Economic Research Service’s 2013 Urban Influence Codes, with a code of 1-2 (i.e. metropolitan areas) classified as “Urban” and a
code of 3-12 (i.e. non-metropolitan areas) classified as “Rural.”
|| The Socioeconomic Status domain includes income, poverty, employment, and education variables.
¶ The Household Composition & Disability domain includes dependent children less than 18 years of age, persons 65 and older, singleparent households, and people with disabilities.
†† The Minority Status & Language domain includes race, ethnicity, and English language proficiency variables.
‡‡ The Housing Type & Transportation domain includes housing structure, crowding, and vehicle access variables.
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FIGURES
Figure 1 – Geographic variation in COVID-19 cases per capita between most and least socially
vulnerable counties by minority status & language.

Footnotes: The most vulnerable quartile of counties (n = 706, top) and the least vulnerable quartile of counties (n =
625, bottom), as indicated by the Minority Status & Language domain of the U.S. Centers for Disease Control’s Social
Vulnerability Index (5). Counties without linked FIPS code or reported COVID-19 cases were excluded. Darker
shades represent counties with more cases per capita.
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Introduction
Coronavirus disease 2019 (COVID-19) has disproportionately impacted marginalized
communities across the United States (US).2 However, early data from clinical trials intended to
develop novel COVID-19 therapeutics revealed that racial/ethnic minority and elderly
populations experiencing the highest COVID-19 incidence, hospitalization, and mortality rates
were not equitably enrolled.40,41
To examine how geographic access might contribute to inequitable trial enrollment, we
descriptively evaluated the geographic proximity of demographic subpopulations to COVID-19
biomedical therapeutic trial sites. We hypothesized that trial sites would be more accessible to
urban populations and subgroups who more often reside in urban areas (racial/ethnic minority
and younger populations).

Methods
For this cross-sectional analysis, we queried ClinicalTrials.gov for trials with keywords
“coronavirus disease 2019”, “COVID-19”, and “SARS-CoV-2” and start dates within the first 8
months of the pandemic (between January 20th and September 20th, 2020). To identify biomedical
therapeutic trials, two authors (R.K., K.A.M.) identified and excluded observational, suspended,
terminated, withdrawn, and non-therapeutic trials.
We geocoded trial site addresses using Google Places API. We calculated drive times from the
center of population for each census tract to the ten geographically closest sites and selected the
site with the shortest time. We stratified rural and urban tracts using 2010 USDA ERS RuralUrban Commuting Area codes. We calculated the proportion of each demographic subgroup
residing within x minutes of the nearest trial site by weighting each tract by population
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demographics (age, race, ethnicity) from the 2015-2019 US Census American Community
Survey (ACS). We calculated median drive times with 95% confidence intervals by bootstrap.
We performed statistical analyses using R Statistical Software v4.0.2 (R Foundation for
Statistical Computing), and plotted maps using ArcMap v10.7.1 (Esri). The University of
Virginia Institutional Review Board deemed this study exempt.

Results
We identified 310 biomedical therapeutic trials with 2095 trial sites, including 246 (79.4%)
randomized trials. Median trial enrollment was 117 (IQR 335). Most included all genders (307
[99.0%]) and adults older than 18 years (285 [91.9%]). 172 (55.5%) were single-center studies
(range 1-117 sites). The most studied interventions included convalescent plasma (37 [11.9%]),
hydroxychloroquine (25 [8.1%]), and remdesivir (11 [3.5%]).
Trial sites were clustered near metropolitan centers (Figure 1A), with corresponding shorter
drive times near urban areas (Figure 1B). Overall, 31.3% of the US population and 76.0% of the
rural population lived > 60 minutes from the nearest trial site. 33.7% of elderly (age 65+), 56.3%
of American Indian/Alaskan Native (AIAN), 32.8% of White, 18.5% of Hispanic, and 10.7% of
Black people lived > 60 minutes from the nearest site.
Rural census tracts (median 85.2 mins [95% CI: 83.9-86.4]) had significantly longer drive times
than urban tracts (18.7 [18.4-18.9]) for all demographic groups (Figure 2). After stratifying by
rurality, only median drive times for AIAN people were still significantly longer than drive
times for the overall population in both urban (AIAN: 20.8 [19.9-21.9]; overall: 18.7 [18.4-18.9])
and rural (104.9 [95.1-114.3]; 85.2 [83.9-87.8]) tracts.

Discussion
Similar to the geographic inaccessibility of clinical trials for other diseases,42 the opportunity to
enroll in biomedical therapeutic trials throughout the first 8 months of the COVID-19 pandemic
was not equitably available across the US. Nearly one-third of the overall US population, over
one-half of AIAN people, and over three-fourths of the rural population lived more than an
hour from the nearest trial site. Rural-urban differences in trial distribution explain longer
overall drive times for White and elderly populations, since these groups disproportionately
resided in rural census tracts. However, the AIAN population faced longer drive times even
when accounting for rurality, suggesting they are uniquely geographically isolated from novel
therapeutics.
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Non-Hispanic and White individuals were well-represented in COVID-19 trials despite rural
trial inaccessibility and lower hospitalization rates.40 Furthermore, the underrepresentation of
Black and Hispanic populations in COVID-19 therapeutic trials is especially striking given their
relative geographic proximity to trial sites and disproportionate hospitalization rates, both of
which suggest greater opportunity for recruitment.40 Factors unexplored herein—including
racism, mistrust, language barriers, and the persistent segregation of well-resourced hospitals—
should be investigated further as potential mediators of decreased trial enrollment.43
Our study has limitations, including that our use of tract centers of population assumes
demographic groups are not clustered within tracts. Tract-level ACS demographic estimates
have some uncertainty. We did not account for vehicle access or reliance on public
transportation. Thus, our tract-level analyses may misestimate travel times for vehicle-less and
demographically segregated urban populations. Our study also has strengths, including our
ability to reliably geocode all sites listed on ClinicalTrials.gov for 310 clinical trials.
Beyond the COVID-19 era, innovations like decentralized, internet-based clinical trials may help
mitigate geographic inequities.44 However, it remains clear that geographic accessibility may
not improve racial/ethnic representation in the absence of additional structural interventions.
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Data Availability. The data analyzed for this study are publicly available from
http://clinicaltrials.gov/.
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and S.D.P. performed statistical analyses. All authors contributed to drafting and revisions of
the manuscript, and all authors reviewed a final version of the work.
Funding. This work was supported by the University of Virginia Global Infectious Disease
Institute.
Prior presentations: An abstract version of this study was presented as a poster at the
AcademyHealth Annual Research Meeting (June 14-17, 2021) and received the Best Student
Poster Award.
Potential conflicts of interest. K.A.M. reports receiving investigator-initiated research funding
from Gilead Sciences, Inc. and receiving grants from the National Institute of Allergy and
Infectious Diseases (NIAID) for work unrelated to this research. All other authors have no
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FIGURES
Figure 1 – (A) Geographic distribution and density of COVID-19 biomedical therapeutic trials
across the contiguous United States; (B) One-way drive time from census tract centers of
population to the nearest COVID-19 biomedical therapeutic trial.

Footnotes: (1A) To display the number of trial sites within an area of geographic proximity, all trial sites were plotted
and those within 25 miles of each other were aggregated into polygons. Circles representing the number of
aggregated trial sites were plotted at the centroid of each polygon. All manipulations were performed using ArcMap
10.7.1. (1B) One-way drive time to the nearest trial was calculated from the centers of population within each census
tract and mapped using ArcMap 10.7.1.
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Figure 2 – One-way drive times to the nearest COVID-19 biomedical therapeutic trial site for
demographic subgroups, stratified by rurality.

Footnotes: This figure displays the percentage of the population with less than (i.e., left of 0% on the x-axis) or greater
than (i.e., right of 0% on the x-axis) a 60-minute drive time to the nearest COVID-19 biomedical therapeutic trial site.
For each sociodemographic subgroup, the median and 95% confidence interval are displayed to the right of the bar.
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